USC Study Guides Better Lung Cancer Treatment Choices

A team at USC just made choosing lung cancer treatment a whole lot easier for thousands of patients facing a difficult diagnosis.

Researchers compared five leading drugs for ALK-positive lung cancer, a rare form that affects about 4% of lung cancer patients and often strikes people who never smoked. Their study, published in Lung Cancer journal, analyzed insurance claims from 940 patients treated between 2016 and 2024.

The challenge was real. Four different drugs currently carry equal recommendations from national medical guidelines, leaving patients and doctors unsure which to choose.

Dr. Jorge Nieva, professor at the Keck School of Medicine, wanted better answers. Clinical trials test drugs on carefully selected patients under perfect conditions, but most real patients are messier: older, sicker, dealing with multiple health issues.

His team dove into insurance data to see how these drugs performed in the real world. They tracked how long patients survived and how long they stayed on each treatment before it stopped working.

The winner was clear. Alectinib showed the strongest results, with patients surviving a median of 46.5 months and staying on treatment for 33.5 months. That beat the oldest drug, crizotinib, on both measures.

Early data hints that lorlatinib, a newer third-generation drug, might help certain patients even more. The numbers weren't definitive yet, but they're promising enough to watch.

The study included patients often excluded from clinical trials: people over 65, those with other medical conditions, patients who weren't in peak health. These are the people doctors actually treat every day.

The Ripple Effect

This research does something powerful beyond just ranking drugs. It shows that newer, more expensive treatments truly work for the full spectrum of patients, not just the healthiest ones in clinical trials.

Dr. Rahul Mudumba, co-author of the study, believes this approach could reshape how medical guidelines get written. In a year or two, with more data on the newer drugs brigatinib and lorlatinib, real-world studies like this could redefine the standard of care.

The findings also help doctors personalize treatment. Lorlatinib might work brilliantly for some patients but inconsistently overall, while alectinib delivers more uniform results. Armed with this knowledge, doctors can match treatments to each patient's situation, health status, and risk tolerance.

For the 7,000 Americans diagnosed with ALK-positive lung cancer each year, better information means better outcomes and more hope.